Table 1.

Pretreatment patients characteristics

Variables	Group		P
	Revlimid, 5 mg (n = 26)	Revlimid, 25 mg (n = 34)
Age (y)	63.7 (7.1)	63.1 (7.2)	0.76
Mean (SD), range	50–75	52–81
Gleason	7.1 (1.0)	7.3 (1.1)	0.51
Mean (SD), range	6–9	5–9
Local therapy
Radical prostatectomy	12	12	0.62
Radiation therapy	4	8
Surgery + RT	10	14
Prior ADT	8	11
Prestudy serum testosterone (ng/dL): mean (range)	374 (148–564)	342 (175–569)	1.0
Prestudy PSA (ng/mL)	11.9 (11.9)	12.4 (13.6)
Mean (SD), range	1.4–43.6	1.2–66.2	0.88
Prestudy PSADT (mo)
<3 m	6	10	0.85
3–8.9	13	16
≥9	7	8
Mean (range), 95% CI	0.16 (0.11–0.21)	0.18 (0.13–0.23)
Pretreatment PSA slopes	0.0–0.45	0.03–0.72	0.55